Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | REN | P00797 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6669963 | 1.00 | HTR2A (0.35) | HTR2AHTR6RENCYP3A4KCNH2 | |
| SCHEMBL6666654 | 0.94 | AKT1 (0.33) | HTR2AHTR6RENCYP3A4KCNH2 | |
| SCHEMBL6670507 | 0.94 | AKT1 (0.33) | HTR2AHTR6RENCYP3A4KCNH2 | |
| SCHEMBL6669982 | 0.91 | HTR2A (0.36) | HTR2ASLC6A2SLC6A4HTR2CHTR2B | |
| SCHEMBL6670278 | 0.91 | HTR2A (0.36) | HTR2ASLC6A2SLC6A4HTR2CHTR2B | |
| SCHEMBL6671560 | 0.90 | HTR6 (0.34) | HTR2AHTR6RENCYP3A4KCNH2 | |
| SCHEMBL6669736 | 0.90 | HTR6 (0.34) | HTR2AHTR6RENCYP3A4KCNH2 | |
| SCHEMBL6667998 | 0.85 | HTR2C (0.32) | HTR2CHTR2B | |
| SCHEMBL6671003 | 0.85 | HTR2C (0.32) | HTR2CHTR2B | |
| SCHEMBL6647925 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6762191-B2 | TREATING DISEASES FOR MODULATING OF 5-HT ACTIVITY, CENTRAL NERVOUS SYSTEM DISORDERS, ANXIETY, OBESITY, DEPRESSION, OR A STRESS-RELATED DISEASE | PHARMACIA & UPJOHN COMPANY | 2004-07-13 | — | — | US | claimed |
| US-20030050304-A1 | Therapeutic compounds | PHARMACIA & UPJOHN COMPANY | 2003-03-13 | — | — | US | claimed |
| US-20040214815-A1 | Therapeutic compounds | PHARMACIA & UPJOHN COMPANY | 2004-10-28 | — | — | US | disclosed |
| US-6762191-B2 | TREATING DISEASES FOR MODULATING OF 5-HT ACTIVITY, CENTRAL NERVOUS SYSTEM DISORDERS, ANXIETY, OBESITY, DEPRESSION, OR A STRESS-RELATED DISEASE | PHARMACIA & UPJOHN COMPANY | 2004-07-13 | — | — | US | disclosed |
| EP-1404679-A2 | (HETERO)ARYL SUBSTITUTED BENZOFURANS AS 5-HT LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030050304-A1 | Therapeutic compounds | PHARMACIA & UPJOHN COMPANY | 2003-03-13 | — | — | US | disclosed |
| WO-2003004501-A2 | (HETERO) ARYL SUBSTITUTED BENZOFURANS AS 5-HT LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214815-A1 | Therapeutic compounds | HTR5A, HTR6, HTR1A | HTR2A 23/4885HTR6 2/4885REN 256/4885 |
| US-20030050304-A1 | Therapeutic compounds | HTR5A, HTR6, HTR1A | HTR2A 23/4885HTR6 2/4885REN 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.